FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 755 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR Patients with Early Stage NSCLC Have a Higher TMB in Comparison... October 9, 2020 Genomic Test Helps Identify Thyroid Nodules That Don’t Require Surgery November 30, 2018 FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma February 2, 2024 Time to meet our new chief scientist – Professor KJ Patel October 12, 2022 Load more HOT NEWS ESMO Highlights Key Issues for Patients with Cancer and Their Carers... 2-Time Cancer Survivor Warns Against Breast Implants After 4 Doctors Missed... Does Eating Processed Meat Increase Your Risk for Cancer? Intermittent Fasting
